Background and objective: We previously reported that histogram-based quantitative evaluation for endobronchial ultrasonography (EBUS) B-mode images could differentiate between benign and malignant lesions. However, these images were generated from reconstructed raw radiofrequency (RF) signals and had some limitations. Currently, there are no reports on raw RF signal data to quantitatively differentiate ultrasound information for peripheral pulmonary lesions. Methods: We prospectively hypothesized that RF spectral analysis from EBUS images could reveal sonographic features of peripheral pulmonary diseases. RF data were imported into a frequency spectral analysis software programme, comparing four parameters: mean frequency (MHz); slope; mid-band fit (dB); and yintercept (dB), to differentiate between benign and malignant lesions. Furthermore, we compared subgroup analysis within benign and malignant lesions. Results: RF data from EBUS images were obtained in 146 cases, of which, 106 lung cancers and 40 inflammatory diseases were present. Significant differences were observed for three parameters in benign and malignant lesions (mean frequency: P < 0.05, slope: P < 0.05, yintercept: P < 0.01) with diagnostic accuracy of 61%, 57.5%, 63%, respectively. In subgroup analysis, the acute pneumonia group showed higher mean frequency, higher slope and lower y-intercept patterns compared to mycobacterial and fibrotic diseases (P < 0.05). In malignant lesions, small cell carcinoma showed higher mean frequency, higher slope and lower y-intercept pattern compared to other histopathological lung cancers (P < 0.01). Conclusion: RF analysis might be capable of demonstrating aspects of the lesion's pathological heterogeneity rather than precisely differentiating between benign and malignant lesions.
INTRODUCTION
The bronchoscopic diagnostic yield for peripheral pulmonary lesions (PPL), according to meta-analysis, exceeds 70%, which is superior to previous yields. 1 This improvement is due to the combination of new instruments, such as endobronchial ultrasonography using a guide sheath (EBUS-GS), bronchial navigation systems and thinner bronchoscopes. However, there are few established methods concerning the quantitative analysis of EBUS images for PPL. 2 We previously reported on histogram-based quantitative analysis for EBUS B-mode images to differentiate between benign and malignant lesions. This technique was a simple and versatile method but had some limitations from the methodological standpoint. 3 Nguyen et al. also reported the successful differentiation of malignant and benign lesions through a similar method. 4 During the image-processing procedure, raw radiofrequency (RF) signals that might include potentially useful information concerning the lesion's features are modified and substantially reconstructed. Hence, we hypothesized that raw RF signal analysis could more precisely reflect the lesion's features using ultrasound. The utility of RF signal analysis has been previously proven to be an effective method for diagnosing pathological features in other disciplines, such as gastrointestinal disease, 5, 6 breast cancer 7 and in cardiovascular disease to identify atherosclerotic plaque. 8 This method was also recently reported in the
SUMMARY AT A GLANCE
Endobronchial ultrasonography (EBUS) is widely used for its high diagnostic rate. This is the first report to investigate the quantitative assessment of EBUS radiofrequency (RF) for peripheral pulmonary lesions. RF analysis might be capable of distinguishing pathological heterogeneity of the lesion better than distinguishing benign and malignant, which can contain various pathological subtypes.
respiratory field for EBUS-guided transbronchial needle aspiration (EBUS-TBNA).
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METHODS
This study was performed at the Department of Chest Surgery and the Department of Respiratory Medicine at St. Marianna University School of Medicine Hospital, with ethics approval (HREC ID 2179). Written informed consent was obtained from all patients and the study was registered as a clinical trial UMIN000009724. In this prospective study, 209 consecutive patients who underwent bronchoscopy with EBUS-GS from October 2012 to February 2014 were enrolled, which included a 2-year follow-up (2016) for inflammatory disease cases.
Bronchoscopy was performed with a flexible bronchoscope (BF-P260F or BF-1T260; Olympus, Tokyo, Japan). Imaging of PPL was performed using a miniature ultrasound probe (UM-S20-17S, 20 MHz centre frequency, radial type; Olympus) and a guide sheath (K-201 guide sheath kit; Olympus). With confirmation of the ultrasound probe within the target lesion, the EBUS image and raw RF data were saved to an endoscopic ultrasound processor simultaneously (Endoscopic Ultrasound Center; EU-ME1, Olympus, customized device) with identical gain and dynamic range (contrast) settings for all patients (displayed 9/19 in gain, 4/8 in contrast). After examination, RF data were transferred from the ultrasound processor to the image reconstruction software.
Offline EBUS image reconstruction and data processing were conducted using MATLAB software (MATLAB 2012a; Mathworks, Commonwealth of Massachusetts, USA). Raw RF signals were dissolved from separate frequencies and intensities using the RF file converter Fourier-transform (MAJ-Y0178; Olympus). In each case, spectral tendency was visualized using a frequency spectral viewer (MAJ-Y0179; Olympus).
ROI selection
Before RF data analysis, regions of interest (ROI) were identified, manually segmented and each image was reconstructed by MATLAB software. Excluding artefacts mainly generated from the probe cover, ROI were selected by a range of concentric circles of 3-5 mm from the centre of the probe and sized to be as large as possible within the lesion. We determined a minimal ROI to demonstrate a stable spectrum parameter for precise analysis for small lesions. Using a Phantom model, ROI should be at least 30 in diameter to demonstrate a stable spectrum (Fig. S1 , Supplementary Information). If the lesion was not large enough to segment a minimal ROI, the case was ineligible for analysis.
Frequency spectral analysis
A discovery cohort from the initial 3 months included 32 cases. For each case, a frequency spectrum was composited to detect the proper frequency range for comparison ( Fig. S2 , Supplementary Information). These spectrums revealed ultrasonic echo signals peaked within approximately 13-20 MHz, and this range was chosen for quantitative assessment. To evaluate quantitatively, a straight line of best fit through the RF signal between 13 and 20 MHz centred on 16.5 MHz was defined. This approximate straight line was defined as: y = ax + b, where the slope corresponded to the value of 'a', y-intercept (dB) equalled 'b' and the mid-band fit (dB) was a value of 16.5a + b (Fig. 1A) . Mean spectrum frequency (MHz) within 13-20 MHz was directly calculated for each case spectrum. Figure 1B shows a typical EBUS image and RF 
RESULTS
Patients and diagnosis
Of the 209 enrolled patients who underwent EBUS-GS between 2012 October and 2014 February, 63 patients were excluded for the following reasons: lesions were too small to analyse in 23 patients; 20 were undiagnosed; 10 revealed ground-glass opacity lesions; and 10 patients had metastatic lung cancers. Data from 146 patients were included and analysed. Table 1 shows 146 patients consisting of 106 lung cancers and 40 patients of inflammatory diseases. Of the 106 lung cancers, 62 were adenocarcinomas (including 22 epidermal growth factor receptor (EGFR)-mutant and 2 anaplastic lymphoma kinase (ALK)-positive patients), 28 were squamous cell carcinomas, 6 large cell carcinomas and 10 small cell carcinomas. Forty inflammatory diseases were divided into 21 acute pneumonias (11 cryptogenic organizing pneumonia (COP), 6 infectious pneumonia, 3 atelectasis and 1 acute eosinophilic pneumonia) and 19 mycobacterial and other diseases (16 mycobacterial diseases, 2 non-specific fibrosis and 1 IgG4-related disease).
Spectrum analysis
For basic comparisons between benign and malignant lesions, mean frequency and slope showed higher values for benign lesions and, correspondingly, the yintercept showed lower values (Fig. 2, Table S1 , Supplementary Information). These three parameters showed significant differences (mean frequency; P < 0.05, slope; P < 0.05, y-intercept; P < 0.01, MannWhitney U-test). Receiver-operating characteristic curves were plotted to determine the optimal cut-off values for disease differentiation (Fig. 3) . Using the yintercept parameter, with a cut-off value of −52.054 dB, cancer was diagnosed with a sensitivity of 59.4%, a specificity of 72.5% and an accuracy of 63.0%, which were superior to other parameters (Table S2 , Supplementary Information). 
Subgroup analysis
In further comparison of benign lesions (Fig. 4 , Table S3 , Supplementary Information), acute pneumonia tended to show higher mean frequency, higher slope and lower y-intercept compared to mycobacterial and other diseases (mean value of each parameter: mean frequency of acute pneumonia/mycobacterial and other fibrotic diseases: 16.563/16.363; slope: 0.187/−0.315; y-intercept: −58.549/−51.364, respectively), and these three parameters revealed significant differences (P < 0.05, Kruskal-Wallis test); however, no significant difference was seen for the mid-band fit.
Further analysis was conducted for lung cancers dividing them into four histopathological groups (Fig. 4, Table S3 , Supplementary Information). Of these four subgroups, small cell carcinoma tended to show higher mean frequency, higher slope and lower y-intercept compared to other pathologies (median value of each parameter: mean frequency of adenocarcinoma/squamous cell carcinoma/ large cell carcinoma/small cell carcinoma: 16.286/ 16.474/16.370/16.663; slope: −0.502/0.078/−0.293/0.391; yintercept: −45.477/−54.425/−50.308/−62.901, respectively), with a significant difference in small cell carcinoma and other types of carcinoma (P < 0.01, Kruskal-Wallis test). Moreover, squamous cell carcinoma showed higher mean frequency, higher slope and lower y-intercept compared to adenocarcinoma, with a significant difference (P < 0.01).
DISCUSSION
This is the first report, to the best of our knowledge, to investigate the quantitative assessment of EBUS RF spectrum for PPL. Originally, this study was intended to differentiate between benign and malignant lesions using quantitatively assessed parameters. However, from these results, we found that RF analysis was capable of demonstrating the aspects of the tissue morphology (e.g. heterogeneous or homogeneous tissues).
Currently, there is no analytical proof for differentiating between benign and malignant lesions using RF data pathologically. However, based on the study of Lizzi et al., it is known that the RF spectral slope decreased when scatter diameter becomes larger. 10 Hence, lower frequency signals were reflected in the (dB) ** Figure 4 Box-plot comparison of radiofrequency parameters for each clinical and pathological diagnosis of benign (pneumonia, mycobacterium and other diseases) and malignant lesions (adenocarcinoma, squamous cell carcinoma, large cell carcinoma and small cell carcinoma). Each plot was marked with Q3 + 1.5 IQR, Q3, Q2, Q1, Q1 − 1.5 IQR, respectively. Ad, adenocarcinoma; Large, large cell carcinoma; NTM, non-tuberculosis mycobacteria; Pneumonia, acute pneumonia; Small, small cell carcinoma; Sq, squamous cell carcinoma; TB, tuberculosis. *P < 0.05, **P < 0.01.
lesion heterogeneously as mixed-sized scattering. On the other hand, higher frequency signals tend to be reflected in lesions consisting of homogeneous smaller scattering. 10 In our study, acute pneumonia and small cell carcinoma showed higher mean frequency, higher slope and lower y-intercept patterns, suggesting these pathologically consisted of homogeneous small components in the lesion. In this study, COP and infectious pneumonia were the two major causes of acute pneumonia. Pathological lesions for COP are usually non-fibrotic and non-destructive compared to other interstitial pneumonias and are treated as other acute pneumonias.
11
Mycobacterial diseases show hypersensitive reactions to antigen with fibrosis and distortion of the lung architecture, which consisted of pathologically heterogeneous components with necrosis in the lesion. In lung cancer, small cell carcinoma is originally defined by tumour cell size, that is less than the diameter of three lymphocytes. 12 Pathological small and homogeneous components were ultrasonically perceived as small scattering that led to reflect higher frequency signals.
We additionally confirmed RF signals in surgically resected tissue to compare local histology and ultrasonic information in some cases. Although small cell carcinoma showed similar results in ex vivo assessment, adenocarcinomas that contain fibroelastic changes ultrasonically showed different analytical patterns for each part of the component, and this heterogeneity of the lesion led to reflect lower frequency signal patterns (Figs S3, S4, Supplementary Information). According to the past reports analysing the RF spectrum of lymph nodes, 5,9 malignant lesions showed higher slope and lower echoic signal intensities, which were inconsistent with our results. For pancreatic tumours pathologically diagnosed as adenocarcinoma, metastatic lymph nodes show a higher slope and a lower echoic signal intensity. 5 In lung cancer, malignant lymph nodes, which contain pathologically diagnosed adenocarcinoma (70.2%), non-small-cell carcinoma (NOS, not otherwise specified (13.2%)) and small cell carcinoma (9.9%), showed a higher slope and a lower echoic signal intensity. 9 It may be difficult to make a simple comparison between primary lung lesions and lymph nodes, which were basically different in original composition and pathological modification, but this has not been fully investigated in previous reports. Moreover, ultrasound devices were also different in radial and convex types or range of frequency. However, our analytical results indicate that spatial variations in scatter size will produce correlated perturbations in the spectral slope and intercept.
When we focus our discussion on clinical utility, RF analysis for PPL was useful in differentiating COP and adenocarcinoma, which were frequently difficult to distinguish on computed tomography (CT) and EBUS imaging (Fig. 5) . In other situations, it may be useful for bronchoscopic examinations to detect the precise location for EBUS biopsy in central malignant lesions with peripheral atelectasis. In future, real-time analysis using bronchoscopy may have the potential to shorten examination times and increase the diagnostic yield to support pathological information ultrasonically.
This study had some limitations. First, the dedicated software for recording raw RF data and the image analyser is as of this writing, not commercially available. Intensity (dB) Figure 5 Radiofrequency analysis could distinguish between adenocarcinoma and cryptogenic organizing pneumonia, where computed tomography and endobronchial ultrasonography were unable to distinguish between malignant and benign lesions.
Hence, the number of patients was limited to a single institution. Second, due to the difference of indication for bronchoscopic examinations, there was a disproportion in the number between benign and malignant lesions, and this resulted in decreased reliability for statistical analysis. Third, the echogenic information was quantitatively different for ROI sizes. Although over 60% of malignant lesions were analysed with an ROI of more than 180 , 60% of benign lesions were less than 180 on ROI. Finally, cancer diagnostic accuracy was low (63.0%) because of containing various pathologies in each malignant and benign group. Where RF spectral analysis was not able to precisely confirm malignancy, further work is needed to confirm the potentially additive benefits of RF analysis with ultrasound analysis.
Recently, genetic diagnoses have gained importance for lung cancer rather than pathological diagnosis for selecting effective and valid medication. At the same time, a reliable approach for sample collection is needed, not only to increase the diagnostic yield, but also to harvest an adequate sample with EBUS-GS for the initial biopsy and re-biopsy. The elasticity of the lesion might be foreseeable by real-time RF analysis in PPL and contribute in ultrasonically choosing the most suitable location for biopsy.
In conclusion, RF analysis might be capable of demonstrating the aspects of the lesion's pathological heterogeneity rather than precisely differentiating between benign and malignant lesions. In subgroup analysis, acute pneumonia and small cell carcinoma showed higher mean frequency, higher slope and lower y-intercept patterns, which suggested pathological homogeneity.
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